Novanme PharmaceuticalCo., Ltd. successfully completes second round of financing

,NovanmePharmaceuticalCo., Ltdannounced the completion of the second round of financing, successfully obtained $13.8 million in fundsIn addition to Atlas, an internationally renowned venture capital firm involved in the first round of capital injections, investors include Fidelity Asia Ventures(
Fidelity Asia Ventures) and Fidelity Biotechnology(
Fidelity Biosciences)Founded in China in2
005, Novanme is an outsourced commercialization service for pharmaceutical and biological companies, including outsourcing programs to assist drug clinical trials
registernew drugs in China and provide commercialization services to multinational companiesNovanme's unique business model helps international pharmaceutical products take full advantage of China's cost advantages and maximize the potential of the Chinese marketOver the past few months, Novanme has established strategic partnerships with multinational pharmaceutical companies such as Sanofi-Anvant , Baxter and Meda to continue to expand and strengthen Novanme's product lines in the areas of tumor , diabetes , respiratory , urological and central nervous system With partnerships with leading companies in research, development, registration and distribution,
services provided by Novanme accelerate the of the development and approval process for drug , benefit patients and doctors in China Mark Lotter, co-founder and chief executive of Novanme, commented on the financing: "Access to the second round of funding is a milestone for Novanme's development in China Not only does it allow us to continue to expand and strengthen our portfolio of products in many important therapeutic areas
enableus us to play an increasingly important role in china's pharmaceutical development According to the , the proceeds of novo-Med ire's second round of financing will be used to introduce new drugs, strengthen commercial operations and drug research and development capabilities (
Zhang Xu)